HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
USPH
U.S. Physical Therapy, Inc.
USPH lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
USPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
USPH's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
USPH PE Valuation
USPH has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
USPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
USPH has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
USPH has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus USPH up 38%.
USPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.22 | +35% |
| Q3 2023 | $1.72 | -42% |
| Q2 2023 | $1.93 | -34% |
| Q1 2023 | $2.16 | -25% |
| Q4 2022 | $2.25 | -6.6% |
| Q3 2022 | $2.98 | +26% |
| Q2 2022 | $2.92 | +26% |
| Q1 2022 | $2.87 | +15% |
| Q4 2021 | $2.41 | -2.8% |
USPH earned $2.38 per share over the past year, up 38% from the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over USPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
USPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.6M | +13% |
| Q2 2026 | $214.1M | +8.5% |
| Q1 2026 | $198.3M | +7.9% |
| Q4 2025 | $202.7M | +12% |
| Q3 2025 | $197.1M | +17% |
| Q2 2025 | $197.3M | +18% |
| Q1 2025 | $183.8M | +18% |
| Q4 2024 | $180.4M | +17% |
USPH's revenue has grown year over year for 22 quarters in a row: $223M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -1.6 points |
| Q2 2026 | 10% | -2.4 points |
| Q1 2026 | 6.3% | -4.4 points |
| Q4 2025 | 8.3% | +0.2 points |
| Q3 2025 | 13% | +4.1 points |
| Q2 2025 | 13% | +0.9 points |
| Q1 2025 | 11% | +1.5 points |
| Q4 2024 | 8.1% | +8.6 points |
USPH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over USPH on cash flow, with more consistent year-over-year improvement.
USPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +32% |
| Q2 2026 | $29M | -8.2% |
| Q1 2026 | -$1.6M | +$5.7M |
| Q4 2025 | $21M | +24% |
| Q3 2025 | $15.6M | -20% |
| Q2 2025 | $31.6M | +19% |
| Q1 2025 | -$7.3M | -381% |
| Q4 2024 | $16.9M | -31% |
USPH generated $69M in free cash flow over the past year, up 21% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over USPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
USPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -142K shares |
| 1 year | -1.8% | -276K shares |
| 3 years | -0.4% | -59K shares |
| 5 years | +16% | +2M shares |
| Available history | +17% | +2.2M shares |
USPH has 15M diluted shares, down 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
USPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.0x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
USPH's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
USPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.9 | Overbought |
| Stochastic | 86.8 | Overbought |
USPH's weekly RSI is 73 (overbought) and its Stochastic is 87 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
USPH PE vs Healthcare Sector
| Metric | USPH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
USPH has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
USPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.9 | 11% above |
| 20 week MA | $82.1 | 20% above |
| 50 week MA | $78.1 | 26% above |
| 100 week MA | $79.1 | 25% above |
| 200 week MA | $88.4 | 12% above |
USPH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
USPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $114.0 | $120.9 | +6% |
| 2021 | $120.9 | $95.7 | -21% |
| 2022 | $95.7 | $81.4 | -15% |
| 2023 | $81.4 | $93.1 | +14% |
| 2024 | $93.1 | $90.9 | -2.4% |
| 2025 | $90.9 | $81.0 | -11% |
| 2026 YTD | $81.0 | $98.6 | +22% |
USPH has the edge over HIMS on returns for 2026, with the stronger performance.